Recursion Pharmaceuticals, Inc. (BMV:RXRX)

Market Cap	38.32B
Revenue (ttm)	801.35M
Net Income (ttm)	-13.12B
Shares Out	n/a
EPS (ttm)	-32.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,894
Average Volume	30,417
Open	78.31
Previous Close	n/a
Day's Range	77.40 - 78.31
52-Week Range	70.95 - 219.00
Beta	n/a
RSI	37.42
Earnings Date	Feb 27, 2026

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 800
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: RXRX

Financial Performance

In 2024, Recursion Pharmaceuticals's revenue was $58.84 million, an increase of 32.00% compared to the previous year's $44.58 million. Losses were -$463.66 million, 41.3% more than in 2023.

Financial numbers in USD